Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination chemotherapy for osteosarcoma.

C B Pratt, G Rivera, E Shanks

    Cancer Treatment Reports
    |February 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    CARBON NUTRITION AND THE REGULATION OF UPTAKE HYDROGENASE ACTIVITY IN FREE-LIVING AND SYMBIOTIC ANABAENA CYCADEAE.

    The New phytologist·2021
    Same author

    Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling.

    Cancer letters·2021
    Same author

    Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration.

    Alzheimer's research & therapy·2020
    Same author

    Corrigendum to "Tocotrienols: the unsaturated sidekick shifting new paradigms in vitamin E therapeutics" [Drug Discov. Today 22 (December (12)) (2017) 1765-1781].

    Drug discovery today·2018
    Same author

    Wnt signaling in triple-negative breast cancer.

    Oncogenesis·2017
    Same author

    Gene Microarray Analyses of Daboia russelli russelli Daboiatoxin Treatment of THP-1 Human Macrophages Infected with Burkholderia pseudomallei.

    Current molecular medicine·2015
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Adjuvant chemotherapy combining adriamycin, cyclophosphamide, and high-dose methotrexate with citrovorum factor improved outcomes for osteosarcoma patients. This treatment strategy reduced the risk of pulmonary metastases and increased disease-free survival.

    Area of Science:

    • Oncology
    • Medical Research
    • Clinical Trials

    Background:

    • Osteosarcoma poses a significant risk of pulmonary metastases after amputation.
    • Effective adjuvant therapies are crucial for improving patient outcomes.

    Purpose of the Study:

    • To evaluate the efficacy of adjuvant combination chemotherapy in patients with localized osteosarcoma.
    • To assess the impact of this regimen on disease-free survival and overall survival.

    Main Methods:

    • A cohort of 24 patients with "clinically localized" osteosarcoma received adjuvant adriamycin-cyclophosphamide-high-dose methotrexate-citrovorum factor chemotherapy post-amputation.
    • A separate group of 16 patients with non-localized disease also received the same combination chemotherapy.

    Main Results:

    Related Experiment Videos

    • Of the 24 localized osteosarcoma patients, 13 remained tumor-free for 11-48 months, with a median disease-free survival of 18 months and median survival of 27 months.
    • No relapses occurred in patients disease-free beyond 23 months.
    • Three out of 16 patients with non-localized disease achieved tumor-free survival at 8, 17, and 19 months.

    Conclusions:

    • Adjuvant combination chemotherapy demonstrates promising results in managing localized osteosarcoma, significantly reducing metastasis risk.
    • The regimen shows potential benefit even in some patients with non-localized disease.
    • Further research is warranted to optimize treatment protocols and manage treatment-related toxicities.